The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: Systematic review and economic evaluation

Health Technology Assessment

Volumn 12, Issue 15, 2008, Pages

  Hind, D ^a   Tappenden, P ^a   Tumur, I ^a   Eggington, S ^a   Sutcliffe, P ^a   Ryan, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; WARFARIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ECONOMIC ASPECT; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER DISEASE; LIVER METASTASIS; LIVER TOXICITY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; TRANSAMINITIS; VOMITING; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; META ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 46949092114     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12150     Document Type: Review

References (170)

1. Lloyd-Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 201;5(25).
2. National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Technology Appraisal Guidance No. 33. London: NICE; 2002
3. Cancer Research UK. Statistics: colorectal cancer. London: Cancer Research UK. 2004.
4. Rowan S, Gautrey M, Quinn MJ. Cancer registrations in England, 2001. London: Office for National Statistics; 2004.
5. Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence in Wales 1992-2001. 2004.
6. Quinn M, Babb M, Broch A, Kirby L, Jones J. Cancer trends in England and Wales 1950-1999. Studies in Medical and Population Subjects No. 66. London: The Stationery Office; 2001.
7. Willett W. The search for the causes of breast and colon cancer. Nature 1989;338:389-94.
8. Reddy B, Engle A, Katsifis S, Simi B, Bartram HP, Perrino P. et al. Biochemical epidemiology of colon cancer: effect of types of dietary fiber on fecal mutagens, acid, and neutral sterols in healthy subjects. Cancer Res 1989;49:4629-35.
9. Potter JD. Reconciling the epidemiology, physiology, and molecular biology of colon cancer. JAMA 1992;268:1573-7.
10. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66:1191-308.
11. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma-carcinoma sequence in large bowel. Lancet 1978;i:245-7.
12. American Joint Committee on Cancer. Collaborative staging manual and coding instructions. 2004.
13. South West Cancer Intelligence Service. Data held on file: audit study of patients with colorectal cancer undertaken in the Wessex Region 1991-1995. 1995.
14. Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ 2004;321:805-8.
15. Centre for Reviews and Dissemination. The management of colorectal cancers. Effective Health Care 1997;8(3). York: CRD.
16. NHS Executive. Improving outcomes in colorectal cancer: the research evidence. London: NHS Executive; 2000.
17. Seymour MT, Stenning SP, Cassidy J, and the Colorectal Cancer Working Party of the UK Medical Research Council. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol (R Coll Radiol) 1997;9:248-51.
18. Young A, Rea D. ABC of colorectal cancer: treatment of advanced disease. BMJ 2000; 321:1278-80.
19. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7(32).
20. National Institute for Clinical Excellence. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. Technology Appraisal Guidance No. 61. London: NICE;2003.
21. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
22. Poon MA, O'Connel MJ, Wieand HS, Krook JC, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
23. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittan J, Marquet J. et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96.
24. Madajewicz S, Petrelli N, Rustum YM. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984;44:4667-9.
25. Lokich JJ, Ahlgren JD, Gullo JJ, et al. Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid Atlantic Oncology Programme Study. J Clin Oncol 1989; 7:425-32.
26. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etiene PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup Study. J Clin Oncol 1997;15:808-15.
27. Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first- or second-line treatment of advanced or metastatic colorectal cancer. Br J Cancer 2002; 87:1216-220.
28. Aranda E, Diaz-Rubio E, Cervantes A, Antón-Torres A, Carrato A, Massuti T, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastro-Intestinal Tumor Therapy (TTD) Study. Ann Oncol 1998;9:727-31.
29. Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-26.
30. Levi F. Chronopharmacology of anticancer agents. In Redfern P, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin: Springer; 1997. pp 299-331.
31. National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in colorectal cancers (manual update). London: NICE; 2004.
32. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999; 35:1796-804.
33. Jonker DJ, Maroun JA, Kocha W Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000:82:1789-94.
34. Irinotecan: summary of product characteristics. Electronic Medicines Compendium 2005. http://www.medicines.org.uk
35. Joint Formulary Committee. British National Formulary 47. London: British Medical Association; 2004.
36. Electronic Medicines Compendium (eMC). 2004. http:// www.medicines.org.uk
37. Oxaliplatin: summary of product characteristics. Electronic Medicines Compendium 2005.
38. Atkin WS. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359:1291-300.
39. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
40. Cassidy J. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. ASCO Annual Meeting, 2004. J Clinical Oncology 22(145): July 15, Suppl. 3509.
41. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53.
42. Seymour MT. Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) Trial. European Society of Medical Oncology; 2004. Ann Oncol 2004;15(Suppl.): Abstract SIN.
43. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
44. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. JAMA 1995;273:408-12.
45. Parmar MK, Torri V, Stewart L Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
46. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
47. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [published erratum appears in Lancet 2000:355:1372]. Lancet 2000; 355:1041-7.
48. Köhne CH, Van Cutsem E, Wils JA, Bokemeyer C, El-Serefi M, Lutz M et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986 [abstract]. Proc Am Soc Clin Oncol 2003;22:254.
49. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
50. Comella P, Massidda B, Farris A. Oxaliplatin vs irinotecan plus leucovorin/fluorouracil i.v. bolus as first-line treatment of advanced colorectal carcinoma. ESMO Annual Meeting, 2002. http://www.asco.org/ portal/site/asco/menuitem.34d60f5624ba07fd506fe310ee37a10d/ ?vgnextiod=76f8201eb61a7010VgnVCM100000ed730adlrcrd&vmview= abst_detail_view&confid=16&absrractid=645
51. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
52. Aventis Pharma. Submission to the National Institute of Clinical Excellence (NICE) on Campto® (irinotecan) for colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed [review]. Industry submission to NICE; 2004.
53. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al., Italian Trials in Medical Oncology. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100:279-87.
54. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med 2004;350:2335-42.
55. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
56. Köhne CH, Van Cutsem E, Wils J, Bokemeyer C, El-Serafi, Lutz M, et al. Phase III study of weekly high-dose infusional 5-fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. [submitted as commercial in confidence]. 2004.
57. Comella P, Massidda B, Filippelli G. Oxaliplatin (OXA) plus folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus (OXAFAFU) versus irinotecan (IRI) plus FA and FU i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): activity and toxicity results of the SICOG 0103 randomized trial. Proc Am Soc Clin Oncol 2004;22(145): Abstract 4143.
58. Comella P. Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103. Clin Colorectal Cancer 2003; 3:186-9.
59. Comella P, Massidda B, Filippelli G. Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0103) randomized study. Proc Am Soc Clin Oncol 2003;22(280):Abstract 1123.
60. Medical Research Council. Academic inconfidence data from the FOCUS trial submitted by the Clinical Trials Unit. 2004.
61. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6:81-91.
62. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001; 12:435-42.
63. Ross PJ, Popescu D, Cunningham A. Adjuvant and palliative chemotherapy for colorectal cancer in patients aged 70 years or older. Proc Am Soc Clin Oncol 1998;17;1096.
64. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment. N Engl J Med 1999;341:2061-7.
65. Marcuello E, Navarro M, Cervantes AS, Anton A, Massuti B, Carrato A, et al. TTD Spanish Cooperative Group Biweekly oxaliplatin (OXA) plus weekly 48 h continuous infusion (CI) of 5FU (TTD regimen) for the first-line treatment of advanced colorectal cancer (ACC). Ann Oncol 2000; 11:213P.
66. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-8.
67. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF, Age, sex and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002;20:1192-202.
68. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 1998;352:1634]. Lancet 1998; 352:1407-12.
69. Cunningham D, Glimelius B. V301 Study Group. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. Semin Oncol 1999;26:6-12.
70. Becouarn Y, Mousseau M, Gamelin E. CPT-11 and L-OHP combination versus alternated combination of LVSFU2 + CPT-11/LV5FU2 + L-OHP in 5-FU resistant advanced colorectal cancer (CRC): preliminary results. Eur J Cancer 1999;35:S71.
71. Adenis A, Douillard JY, Lacroix H-Randomized phase II-III trial of oxaliplatin (OXA) with 5-flourouracil (5FU) continuous infusion (CI) versus a control arm with either 5FU or irinotecan (CVT11) in previously treated metastatic colorectal cancer (MCRC) patients (Pts). ASCO OnLine 2000; 1088.
72. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002; 13:1558-67.
73. Smithies A, Stein K. Wessex Institute for Health Research and Development, Irinotecan as second-line chemotherapy in colorectal cancer. University of Southampton; 1999.
74. Selke B, Lebrun T, Comte S [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review]. Bull Cancer 2003; 90:143-9.
75. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-14.
76. Stewart G, Chau I, Norman A, Katopodis O, Topham C, Middleton G, et al. Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. ASCO Annual Meeting; 2004. J Clin Oncol [ABCO Annual Meeting Proceedings (Post Meeting Edition)] 2004;22(145): 3622.
77. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
78. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47.
79. Grothey A, Buechele T, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, et al. Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002;21:Abstract S12.
80. Zori Comba A, Blajman C, Richardet E. Bimonthly oxaliplatin (L-OHP) with (A) or without (B) flouracil (FU) and leucovorin (FA): proven evidence of synergism in a phase II: randomised trial. ASCO OnLine 1999; 953.
81. de Gramont A, Cervantes A, Andre T. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer [abstract]. ASCO Annual Meeting Proceedings 2004. J Clin Oncol 2004;22.
82. Giacchetti S. First-line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). ASCO Annual Meeting, 2004. 40th Annual Meeting, New Orleans, USA.
83. Levi F, Zidani R, Vannetzel JM. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Nar Cancer Inst 1994;86:1608-17.
84. Cassidy J, Cunningham D, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Mainwaring P. Life: longevity improvement with front-line eloxatin. A randomised trial evaluating Eloxatin (oxaliplatin) combined with 2 different 5-FU regimens followed by irinotecan in patients with previously untreated advanced colo-rectal cancer: preliminary results [abstract]. Proc Am Soc Clin Oncol 2003;22:265.
85. Grothey A, Deschler B, Kroening H. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21(Issue 129a): Abstract S12; 3530.
86. Exquis B, Aapro M, Kohler S. Oxaliplatin (with 5FU and leucovorin) in patients above age 70 suffering from metastatic colorectal cancer: an observational study. ASCO Annual Meeting, 2004. J Clin Oncol 22(145, July Suppl.):8042.
87. Botto HG. Combination of oxaliplatin (OXA) and 5-fluorouracil, leucovorin (5-FU/LV), as first-line therapy, in elderly patients >70 years, with metastatic colorectal cancer. ASCO Annual Meeting, 2004. J Clin Oncol 22(145, July Suppl.):3717.
88. Andre T, Figer A, Cervantes A, Lledo G, Flesch M, Maindrault-Goebel F, et al. Folfox7 compared to Folfox4: preliminary results of the randomised optimox study [abstract]. Proc Am Soc Clin Oncol 2003;1016.
89. Figer A, Perez N, Carola E, Andre T, Chirivella I, Lledo G, et al. 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:3571.
90. Maindrault-Gœbel F, Louvet C, Andre T, Carola E, Gilles V, Garcia M, et al. Oxaliplatin reintroduction in patients pretreated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer (MCRC). Ann Oncol 2000;11:216P.
91. Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin [abstract]. Proc Am Soc Clin Oncol 2003; 22:252.
92. Andre,T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al. Aimery Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8.
93. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial [see comment]. J Clin Oncol 2003; 21:2059-69.
94. Cunningham D, Zalcberg JR, Rath U, Oliver I, Van Cutsem E, Svensson C, et al. final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997;8:407]. Ann Oncol 1996; 7:961-5.
95. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-63.
96. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16:2943-52.
97. Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (SFU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial [abstract]. Proc Am Soc Clin Oncol 1997;16:228a.
98. Mel JR, Feliu J, Camps C, Escudero P, Aparicio J, Menendez D, et al. Tomudex (raltitrexed) in elderly patients with advanced colorectal cancer (ACC): an effective palliative treatment. Proc Am Soc Clin Oncol 2000;19:1000.
99. Franchi F, Pastore C, Caporale A, Fabiani O, Rossi L, Seminara P. Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: a case series. Gerontology 2003; 49:324-7.
100. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14.
101. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14:13-16.
102. Adson MA. Resection of liver metastases. When is it worthwhile? World J Surg 1987;11:511-20.
103. Bismuth H, Adam R, Levi F, Farabos C, Waechter E Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20.
104. -2 with 5-FU/FA (LV5FU2 or LFSFUS) in first-line metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21:639c.
105. Ho WM, Mok TS, Ma BB, Lim B, Lai PB, Chui A, et al. Liver resection after irinotecan (CFF-11), 5-fluorouracil (5FU) and folinic acid (FA) for patients (pts) with unresectable liver metastases (mets) from colorectal cancer (crc). Proc Am Soc Clin Oncol 2003; 22:1253.
106. Piedbois P. Intravenous CFF-11/5-FU/LV and hepatic artery infusion pirarubicin in non operable liver metastases from colorectal cancer. A study of the A.E.R.O. Group [abstract]. Ann Oncol 2002; 13:291P.
107. Zelek L, Bugat R, Cherqui D, Ganem G, Valleur P, Guimbaud R, et al. European Association for Research in Oncology, Creteil, France. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial) [see comment]. Ann Oncol 2003;14:1537-42.
108. Pozzo C, Basso M, Cassano A, Quirino A, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9.
109. Slater R, Radstone D, Matthews L, McDaid J, Majeed A. Hepatic resection for colorectal liver metastases after downstaging with irinotecan improves survival. Proc Am Soc Clin Oncol 2003; 22:1287.
110. Giacchetti S, Itzhaki M, Gruia G. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemothrapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
111. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
112. Köhne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group study 40952. J Clin Oncol 2003;21:3721-8.
113. Petrou S, Campbell N. Stabilisation in colorectal cancer. International Journal of Palliative Nursing 1997;3:275-80.
114. Medical Research Council. Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing (FOCUS) clinical protocol (version 6). 2003; CR08:1-90. London: MRC.
115. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004.
116. van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. Semin Oncol 1999;26:13-20.
117. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994.
118. Graf W, Pahlman L, Bergstrom R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994;70:559-63.
119. Weiss GB, Bunce H III, Hokanson JA. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer trials. Control Clin Trials 1983; 4:43-52.
120. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a metaanalysis. Lancet 2000;356:373-8.
121. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
122. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation (review of Guidance No. 33). Technology Assessment Report submitted to NICE; 2005.
123. British Medical Association. British National Formulary 48. London: BMA; 2004. URL: http://www.bnf.org/bnf/
124. Netten A, Curtis L. Unit costs of health anal social care. Canterbury: Personal Social Services Research Unit; 2004.
125. Summerhayes M, Wanklyn SJ, Shakespeare RA, Lovell J. Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced coiorectal cancer.Journal of Oncology Pharmacy Practice 1997; 3:24-30.
126. Boland J, Haycox A, Bagust A, Fitzsimmons L. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technol Assess 2003;7(36).
127. Netten A, Dennett J, Knight J. Unit costs of health and social care. Canterbury: Personal Social Services Research Units; 1999.
128. Schmitt C. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. Anticancer Drugs 1999;10:617-23.
129. Kerr D. O'Connor KM. An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. Journal of Medical Economics 1999;2:123-32.
130. Sanofi-Synthelabo. The use of oxaliplatin for the treatment of advanced colorectal cancer (review of NICE guidance no. 33). Industry submission to NICE; 2004.
131. Schmitt C, Levy-Piedbois C, Frappe M, Durand-Zaleski I, Gruia G, Alakl M, Rougier P. Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer. Ann Oncol 2000;11:202P.
132. Elliott R. An analysis of drug costs in the management of chemotherapy-related side effects in advanced colorectal cancer. A comparison between raltitrexed ('Tomudex') and 5-fluorouracil plus folinic acid. Journal of Oncology Pharmacy Practice 1996; 2:186-90.
133. Vaiani M, Trippoli S, Messori A. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2001; 344:305-6.
134. Trippoli S, Vaiani M, Cartel F, Messori A. Cost-effectiveness of irinotecan in advanced colorectal cancer. Ann Oncol 2000; 11:899-900.
135. Ross P. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996; 32A(Suppl 5):S13-17.
136. Gautie L, Mogenet I, Puisset F, Bonhomme C, Canal P. The cost of palliative chemotherapies for metastatic colorectal cancer: A retrospective study conducted at the Claudius Regaud Institute. Journal d'Economie Medicale 2002;20:401-8.
137. Focan C. Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. Chronobiol Int 2002;19:289-97.
138. Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterology 2003; 50:1903-9.
139. Poston G, Benjamin IS, Diamond T, Finch-Jones M, Parks RW, et al. Costs of neoadjuvant chemotherapy and surgery in patients with liver
140. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first-line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677-83.
141. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000;11:157-61.
142. Nicholls CJ, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. Journal of Medical Economics 2001; 4:127-35.
143. Nicholls C, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone. Journal of Medical Economics 2001; 4:115-25.
144. Groener MGH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999:10:283-8.
145. Monthly index of medical specialties. London: Haymarket Medical; 2000 (September)
146. Department of Health. NHS reference costs. 2003.
147. Royal Marsden Drug and Therapeutics Advisory Committee. Prescribing guidelines. London: Royal Marsden; 2000 (September).
148. Devita VT Jr, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: Lippincott-Raven 1997.
149. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics 2000; 17:361-70.
150. Cancer Research UK. URL: http://www.cancerresearchuk.org/images/11632/ briefsheetbowel_0403.pdf. Accessed 2004.
151. http://www.cancercumbria.org.uk/hobsons_choice.pdf. Accessed 2004.
152. http://www.nature.com/bjc/press_releases/press_release_47.html. Accessed 2004.
153. Bouzid K, Khalfallah S, Tujakowski J, Piko B, Purkalne G, Plate S, et al. Irinotecan Study Group. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 2003;14:1106-14.
154. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-9.
155. Graeven U, Schmiegel W. Colon carcinoma. Consensus of therapeutic strategies. Internist 2000; 41:876-85.
156. Kalofonos HP, Skarlos D, Bafaloukos D, Papakostas P, Bamias A, Janinis J, et al. A phase II study with CFF-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. Cancer Invest 2003;21: 855-62.
157. Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 2000; 11: 1045-51.
158. Pozzo C, Pyrhonen S, Bodrogi I. A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), 'Mayo regimen', in first-line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC). Eur J Cancer 1999; 35:(S70):Abstract 213.
159. Recchia F, De Filippis S, Rosselli M, et al. Randomized phase II study of oxaliplatin (OX) or CPT-11 (CPT) combined with bimonthly leucovorin (L) and 5-flourouracil (5-FU) in metastatic colorectal cancer (MCC). Preliminary report. ASCO OnLine 2000.
160. Rougier P, Cunningham D, Roth AD. Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC). Eur J Cancer 1999; 35:206.
161. Ulrich-Pur H, Brugger S, Kornek GV. Randomized phase II study of CVT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC). Eur J Cancer 1999;35:(S72): Abstract 225, 72-3.
162. Bollina R, Toniolo D, Belloni P, Cozzi C, Clerici M. Oxaliplatin (LOHP) and Irinotecan (CPT11)- Oxiri-: Phase I/II Study in 5FU (F) refractory advanced colorectal cancer (ACRC) elderly patients (pts), a second-line treatment. American Society of Clinical Oncology; 2001.
163. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91:1453-8.
164. Comella P, Farris A, Lorusso V, Palmeri S, Maiorino L, De Lucia L, et al. Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic coiorectal carcinoma. Br J Cancer 2003; 89:992-6.
165. Lopez-Gomez L, Escudero P, Yubero A, Feliu J, Salud A, Galan A, et al. XELOX (capecitabine and oxaliplatin) as 1st-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). J Clin Oncol 2004; 22:3688.
166. Rosati et al. A phase II trial of oxaliplatin (L-OHP) and uracil-tegafur (UFT)/folinic acid (FA) for advanced colorectal cancer (ACC) in elderly patients. ASCO Annual Meeting, 2004. J Clin Oncol 22:2793.
167. Cortinovis D, Bajetta E, Di Bartolomeo M, Dognini G, Beretta E, Ferrario E, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. Tumori 2004;90:186-91.
168. Facchini T, Genet D, Berdah JF, Nouyrigat P, Dutin JP, Laplaige P, Haguenauer D. Ratitrexed (Tomudex) has a manageable toxicity profile in elderly pauents with metastatic colorectal cancer: final analysis of a multicentre study. ASCO Annual Meeting, 2000.
169. Paredes M, Garcia D, Mel JR, Escudero P, Camps C, Montalar J, et al. An ongoing Phase II study of tomudex (raltitrexed) in elderly patients with advanced colorectal cancer: an assessment of tolerability and clinical benefit. ASCO Annual Meeting, 1999.
170. Romiti A, Di Seri M, Lacava V, Oliveti A, Bonginelli P, Santuari L, et al. Tolerability of raltitrexed in elderly patients affected with colorectal cancer (CRC). Ann Oncol 2000;11:58-9.